Source: Annual Congress 2010 - New treatments for asthma and COPD
Disease area: Airway diseases

Abstract

Background
Ectoine is a cyclic amino acid, identified as a compatible solute in halophilic bacteria conferring resistance toward stressors like temperature or salt. Ectoine is used for symptomatic treatment of rhinitis sicca, rhinitis allergica and to abate symptoms of neurodermatitis. The mode of action includes protection of biological macromolecules and structures i.e. proteins, membranes and cells.
Aims and Objectives
Results from investigational models demonstrated efficacy of ectoine in reducing inflammation in the airways. Consequently, it was of interest to investigate ectoine in the treatment and prophylaxis of asthma in man.
Method
In a first in human safety, dose finding and efficacy study the effect of ectoine inhalation solution in eighteen patients suffering mild bronchial asthma was investigated. Patients were treated with 0,9% NaCl solution (placebo) and three increasing doses of ectoine inhalation solution administered once daily over 5-7 days as an add-on to maintained standard asthma medication (corticosteroids). Assessment included lung function parameters, fractionated exhaled nitric oxide and inflammation markers in sputum.
Results
The medium dose level of ectoine inhalation solution (13 mg/ml) exhibited the best efficacy with respect to pulmonary function, nitric oxide exhalation (statistically significant), and inflammation markers in sputum. A good safety profile for ectoine inhalation solution was achieved in this study.
Conclusion
The result of our study strongly indicates a potential prophylactic and therapeutic application of inhaled ectoine in patients suffering inflammation of the respiratory tract i.e. asthma or COPD.

Rating:

Share or cite this content

Citations should be made in the following way:
A. Bilstein, T. Meyer, D. Probst (Witten, Gauting, Germany). Safety, dose finding and efficacy of ectoine inhalation solution in patients with mild asthma. Eur Respir J 2010; 36: Suppl. 54, 1160

Member's Comments

No comment yet.

Related content which might interest you: Safety and efficacy of ectoine inhalation solution in patients with inflammation and airway obstruction: The EFECT study Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012 Efficacy and safety of single doses of inhaled LAS100977 in patients with mild to moderate asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Efficacy, safety and acceptance of salbutamol administered via MAGhaler in children with mild to moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 430s Year: 2002 Safety and pharmacokinetics of two dose strengths of ciprofloxacin dry powder for inhalation (DPI) in patients with moderate to severe COPD Source: Annual Congress 2012 - Hot topics in respiratory infections Year: 2012 Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Withdrawal of high-dose inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: a feasibility study in primary care. Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Safety of once-daily QMF149 in patients with persistent asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Tolerability of inhalation of salt particles in COPD patients Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity Year: 2020 The GOLDEN-1 study: Safety and bronchodilatory effects of nebulized glycopyrrolate (EP-101) using high efficiency nebulizer in patients with COPD Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Comparison of efficacy and safety of Obucort Swinghaler with Pulmicot Turbuhaler in mild to moderate severe asthma patients Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 Efficacy and safety of VR475 (budesonide suspension delivered by the VR475 Inhalation System) as add-on treatment in patients with severe asthma (CLEARCUT Study) Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Immunogenicity assessment of intravenous administration of reslizumab in patients with asthma in phase 3 clinical studies Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Efficacy and safety of nebulized glycopyrrolate (EP-101) for administration using high efficiency nebulizer in patients with COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Safety of formoterol Turbuhaler(R) at cumulative dose of 90 {micro}g in patients with acute bronchial obstruction. Source: Eur Respir J 2002; 19: 384 Year: 2002 Efficacy of tiotropium bromide inhalation combined with or without low dose theophylline for moderate to severe stable Chinese COPD patients Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Safety and tolerability of multiple-dose indacaterol, a novel 24-hour β2-agonist, in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005 Safety and efficacy of momethason furoate for usage in school children with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 290s Year: 2003 High or standard initial dose of budesonide to control mild-to-moderate asthma? Source: Eur Respir J 2001; 17: 856-862 Year: 2001